Mobia Medical IPO Closing Market Cap prediction

I'm usually the first to roll my eyes at medtech hype, but Mobia's IPO setup is hard to dismiss. Their share pricing midpoint lands the market cap exactly at the bottom of the target range — meaning they don't need a single day-one pop to qualify. That's not optimism, that's arithmetic. The underlying business isn't smoke and mirrors either. Vivistim is FDA-approved, generating real revenue, and sits alone as the only validated neurostimulation therapy for stroke recovery. In a thirty-billion-dollar market, being the only validated option matters. Yes, the reimbursement picture is messy — Medicare classifying the device as experimental is a genuine headache — and losing nearly fifty million dollars last year doesn't inspire warmth. But Goldman Sachs and BofA don't lend their names to deals they expect to crater on day one. The medtech IPO environment is choppy, sure. But this isn't a speculative bet on future science — it's a device already in the market, backed by big-name underwriters, priced almost perfectly to clear the bar with minimal help. I'd back Yes here: the structural setup is too tidy to bet against, and the downside scenario requires multiple things going wrong simultaneously.